Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of “Buy” from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned an average recommendation of “Buy” from the six research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $17.10.

Several research analysts recently commented on ROIV shares. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th.

Insider Activity at Roivant Sciences

In other news, COO Eric Venker sold 218,041 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the sale, the chief operating officer now owns 896,869 shares of the company’s stock, valued at approximately $9,345,374.98. This trade represents a 19.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 2,439,640 shares of company stock worth $27,451,035 in the last ninety days. 7.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently bought and sold shares of ROIV. Norges Bank bought a new position in shares of Roivant Sciences during the 4th quarter worth about $52,443,000. TOMS Capital Investment Management LP acquired a new position in Roivant Sciences in the third quarter worth about $46,333,000. Invesco Ltd. lifted its stake in Roivant Sciences by 49.7% during the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company’s stock worth $112,563,000 after purchasing an additional 3,159,603 shares during the period. FMR LLC boosted its holdings in Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after purchasing an additional 2,593,910 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after purchasing an additional 2,404,232 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

ROIV opened at $10.67 on Wednesday. The company has a market cap of $7.61 billion, a PE ratio of -71.13 and a beta of 1.26. The stock has a 50-day moving average of $10.78 and a 200-day moving average of $11.44. Roivant Sciences has a 52-week low of $9.96 and a 52-week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, research analysts predict that Roivant Sciences will post -0.92 earnings per share for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.